44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Medical services, namely, cellular starter material collection services featuring human blood-derived biological raw materials that are eventually processed for biopharmaceutical uses and disease treatments
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Promoting the donation of blood plasma by means of arranging and conducting blood plasma donor loyalty and referral incentive rewards programs; administration of blood plasma donor loyalty and referral incentive rewards programs to promote blood plasma collection services and the collection of blood plasma; promoting public awareness of blood disorders, treatment and the impact of blood plasma collection. Providing a website promoting the donation of blood plasma by means of arranging and conducting blood plasma donor loyalty and referral incentive rewards programs; providing a website promoting blood plasma collection services and the collection of blood plasma; providing a website promoting public awareness of blood disorders, treatment and the impact of blood plasma collection.
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Promoting the donation of blood plasma by means of arranging and conducting blood plasma donor loyalty and referral incentive rewards programs; administration of blood plasma donor loyalty and referral incentive rewards programs to promote blood plasma collection services and the collection of blood plasma; promoting public awareness of blood disorders, treatment and the impact of blood plasma collection. Providing a website promoting the donation of blood plasma by means of arranging and conducting blood plasma donor loyalty and referral incentive rewards programs; providing a website promoting blood plasma collection services and the collection of blood plasma; providing a website promoting public awareness of blood disorders, treatment and the impact of blood plasma collection.
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
09 - Appareils et instruments scientifiques et électriques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Non-downloadable software for patients, caregivers and
medical professionals for use in managing pharmaceutical
treatments and administering pharmaceutical preparations;
downloadable mobile applications for patients, caregivers,
and medical professionals for use in managing pharmaceutical
treatments and administering pharmaceutical preparations. Pharmaceutical patient support program providing guidance
and information on pharmaceutical treatment and
administration via non-downloadable software and a
downloadable mobile application.
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Downloadable software in the nature of a mobile application for patients, caregivers, and medical professionals for use in managing pharmaceutical treatments and administering pharmaceutical preparations Providing online non-downloadable software for patients, caregivers and medical professionals for use in managing pharmaceutical treatments and administering pharmaceutical preparations Pharmaceutical patient support program, namely, providing guidance and information to patients, caregivers, and medical professionals on pharmaceutical treatment and administration of pharmaceutical preparations via non-downloadable software and a downloadable mobile application
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Downloadable software in the nature of a mobile application for patients, caregivers, and medical professionals for use in managing pharmaceutical treatments and administering pharmaceutical preparations Providing online non-downloadable software for patients, caregivers and medical professionals for use in managing pharmaceutical treatments and administering pharmaceutical preparations Pharmaceutical patient support program, namely, providing guidance and information to patients, caregivers, and medical professionals on pharmaceutical treatment and administration of pharmaceutical preparations via non-downloadable software and a downloadable mobile application
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Downloadable software in the nature of a mobile application for patients, caregivers, and medical professionals for use in managing pharmaceutical treatments and administering pharmaceutical preparations Providing online non-downloadable software for patients, caregivers and medical professionals for use in managing pharmaceutical treatments and administering pharmaceutical preparations Pharmaceutical patient support program, namely, providing guidance and information to patients, caregivers, and medical professionals on pharmaceutical treatment and administration of pharmaceutical preparations via non-downloadable software and a downloadable mobile application
Educational materials and guides for school staff and administration to educate them on the unique needs and medical nuances of students living with bleeding conditions
09 - Appareils et instruments scientifiques et électriques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Non-downloadable software for patients, caregivers and medical professionals for use in managing pharmaceutical treatments and administering pharmaceutical preparations; downloadable mobile applications for patients, caregivers, and medical professionals for use in managing pharmaceutical treatments and administering pharmaceutical preparations. Pharmaceutical patient support program providing guidance and information on pharmaceutical treatment and administration via non-downloadable software and a downloadable mobile application.
09 - Appareils et instruments scientifiques et électriques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Downloadable mobile application for patients, caregivers, and medical professionals for use in managing pharmaceutical treatments and administering pharmaceutical preparations. Pharmaceutical patient support program providing guidance and information on pharmaceutical treatment and administration via a downloadable mobile application.
09 - Appareils et instruments scientifiques et électriques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Downloadable mobile application for patients, caregivers, and medical professionals for use in managing pharmaceutical treatments and administering pharmaceutical preparations. Pharmaceutical patient support program providing guidance and information on pharmaceutical treatment and administration via a downloadable mobile application.
Printed educational materials and guides for school staff and administration to educate them on the unique needs and medical nuances of students living with bleeding conditions
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Produits pharmaceutiques et vétérinaires ainsi que produits hygiéniques, à savoir, préparations pharmaceutiques pour la prévention et le traitement des saignements causés par des troubles sanguins; produits diététiques pour enfants et malades, à savoir, suppléments alimentaires pour l'état général de la santé et le bien-être; emplâtres en tant que matériel pour pansements, matériel pour pansements, à savoir, pansements médicaux; matières pour plomber les dents et pour empreintes dentaires; désinfectants multi usages; préparations pour détruire les mauvaises herbes et les animaux nuisibles.
Medical devices, namely, vial access system consisting primarily of a docking tray that facilitates direct access to contents of multiple vials containing pharmaceutical preparations for patient infusion.
Medical devices, namely, vial access system consisting primarily of a docking tray that facilitates direct access to contents of multiple vials containing pharmaceutical preparations for patient infusion
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Medical services, namely, cellular starter material collection services featuring human blood-derived biological raw materials that are eventually processed for biopharmaceutical uses and disease treatments
A liquid handling robot has a worktable that supports a rack holding a set of pipette tips. The liquid handling robot also has an arm that is operably suspended above the worktable, where the arm includes a tip receiver that is configured to engage the set of pipette tips. A controller of the liquid handling robot is configured to raise the tip receiver away from the worktable to withdraw the engaged set of pipette tips from the rack. A sensor is fixed relative to the worktable and is operable to emit a beam. A microcontroller monitors the sensor with the arm in a checking position to determine if the rack interrupts in the beam to indicate that the rack stuck to the pipette tips, which is autonomously resolved by the liquid handling robot performing a corrective action.
A filter press device includes a supporting frame and elongated side rails disposed parallel and horizontally on the supporting frame. A following head assembly is disposed on an end portion of the supporting frame, and a following head assembly is movably disposed on another end portion of the supporting frame. The elongated side rails support a combination of filter plates of varying sizes through one or more adapters. An adapter plate interposes between adjacent filter plates of different sizes, providing fluidic communication between the different sized filter plates.
B01D 25/164 - Presses à chambre et à plaque, c.-à-d. dans lesquelles les bords latéraux des éléments filtrants sont calés entre les deux plaques filtrantes successives
A medicinal fluid pooling device may be used to pool multiple containers of medicinal fluid to facilitate administration of the medicinal fluid to a patient. A medicinal pooling device may include spikes covered by spike sheaths which are pierced when a container of medicinal fluid is inserted into the medicinal pooling device. The medicinal pooling device may also include a cover configured to cover the spikes. The medicinal pooling device may also include a fluidic interface which may be used to fluidly connect the medicinal pooling device to an infusion pump or syringe.
A61M 5/162 - Raccords à aiguilles, c.-à-d. raccordements par perforation entre le réservoir et le tube
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
50.
A METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION FROM C-1 INHIBITOR DEPLETED PLASMA
Described is a method for preparing an Immunoglobulin G (IgG) enriched fraction from a Cl- INH depleted plasma supernatant. Isolation of Immunoglobulin G (IgG) enriched fraction from a Cl-INH depleted plasma supernatant provided an alternative starting material for the manufacturing process. In the present invention, Cl-INH depleted plasma supernatant is treated with heparin before further processing.
In some embodiments, a reconstitution or medicinal fluid delivery device includes a transfer engine including two fluidly connected spikes, each configured to pierce a container. A check valve may be disposed between the two spikes to allow unidirectional flow from one container to the other. Physical access to a fluid outlet may be obstructed by a housing until the reconstitution or medicinal fluid delivery device is actuated, whereupon physical access to the fluid outlet is permitted. The reconstitution or medicinal fluid delivery device may be placed on a flat surface and actuated with force applied in a single direction toward the flat surface.
The present invention relates to a method for treatment of menorrhagia in a subject with von Willebrand Disease (VWD) comprising administering a therapeutic amount of recombinant von Willebrand Factor (rVWF) to the subject.
The present invention provides, among other aspects, methods for the treatment of Alzheimer's disease in a subject in need thereof, the method including administration of a therapeutically effective amount of a pooled human immunoglobulin G (IgG) composition to a subject with moderately severe Alzheimer's disease, a subject carrying an ApoE4 allele, or both, where the amount of pooled human IgG is from 300 mg/kg to 800 mg/kg body weight of the subject per two week period, and where the amount is administered in one or more doses during the two week period after initiation of a therapeutic regimen. Also provided, are methods for selecting a treatment regimen for a subject with Alzheimer's disease, including diagnosing the severity of the Alzheimer's disease, determining if the subject carries an APOE4 allele, or both, and assigning a treatment regimen including administration of pooled human immunoglobulin G and/or an anti-beta amyloid monoclonal antibody.
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/06 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux provenant de sérum
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention relates to a method for continuous recovering of a protein from a fluid, comprising precipitating the protein in the fluid and separating the precipitated protein from the fluid. The invention also provides an inclined plate settler that can be used for such continuous protein recovering.
The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A. In some embodiments, the present disclosure provides methods for dosing a hemophilia A patient with a polynucleotide, e.g., a codon-altered polynucleotide, encoding a Factor VIII polypeptide.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
C07K 1/107 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
C07K 1/20 - Chromatographie de partage, de phase inverse ou d'interaction hydrophobe
C07K 1/34 - ExtractionSéparationPurification par filtration, ultrafiltration ou osmose inverse
The AAV compositions comprising an AAV and a buffer. These AAV compositions are appropriate for us in intracerebroventricular (ICV) and intraparenchymal (IPA) administration, as well as other routes of administration and can be provided in frozen, liquid or potentially freeze dried (lyophilized) state.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
59.
VIRAL VECTORS ENCODING RECOMBINANT FIX WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA B
Codon-altered polynucleotides encoding Factor IX variants for expression in mammalian cells are provided, including sequences with high nucleotide sequence identity to the CS02, CS03, CSO4, CS05, and CS06 sequences. Mammalian gene therapy vectors, such as adeno-associated viral vectors, and methods for treating hemophilia B using those vectors are also provided.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
in vitroin vitro methods for screening candidate agents that modulate macrophage activity and function by contacting macrophages with a complex comprising VWF, complement Clq, and cholesterol crystals (CC).
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
Systems and methods providing a clotting factor VIII dosing regimen are disclosed. The systems and methods include determining an estimated pharmacokinetic profile of a patient using a Bayesian model of pharmacokinetic profiles of sampled patients. The systems and methods can determine a first dosing regimen for a first dosing interval including (i) a first dosage and (ii) a first therapeutic plasma protein level in the patient varying over time based at least upon the estimated pharmacokinetic profile. The systems and methods can determine a second dosing regimen for a second dosing interval including (i) a second dosage and (ii) a second therapeutic plasma protein level in the patient varying over time. The estimated pharmacokinetic profile can be adjusted based on previous patient treatments. Further, a user can select which days a dosage is to be applied such that the protein level does not fall below a target trough.
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16C 20/30 - Prévision des propriétés des composés, des compositions ou des mélanges chimiques
G16C 20/50 - Conception moléculaire, p. ex. de médicaments
G16C 20/70 - Apprentissage automatique, exploration de données ou chimiométrie
G06N 7/00 - Agencements informatiques fondés sur des modèles mathématiques spécifiques
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
An infusion system includes a pump unit and a motor unit. The pump unit may be configured to receive and/or retain at least one container of medicinal fluid, and may include a fluid distribution system at least partially engaged with a peristaltic pump head disposed in the pump unit. The motor unit may be removably received in the pump unit and coupled to the peristaltic pump head to drive fluid from the container to a fluid outlet that is couplable to an infusion set.
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/172 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte électriques ou électroniques
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
Provided herein are methods of producing an adeno-associated virus (AAV) product and methods of purifying adeno-associated virus. AAV is loaded onto an affinity resin, wash steps are undertaken at room temperature, and AAV is eluted from the affinity resin at a lower temperature. Various buffers are disclosed for use in the wash steps and elution.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
Methods are provided for treating a patient with viral-based gene therapy that promote persistent transgene expression. The methods include administering to the patient an inhibitor of the interleukin-6 (IL6) signaling pathway or the NCOR2/SMRT histone deacetylation pathway, and a viral-based gene therapy vector. Methods are also provided for assigning viral-based gene therapy to a patient that include determining whether the patient has a genotype sensitizing the patient to persistent infection by a viral-based gene therapy vector by evaluating whether the patient has a mutation in the SMRT/NCOR2 gene associated with reduced SMRT/NCOR2 protein function or in the interleukin-6 receptor (IL- 6R) gene associated with reduced IL-6R function. If the patient has either a mutation in the SMRT/NCOR2 gene associated with reduced SMRT/NCOR2 protein function or a mutation in the IL-6R gene associated with reduced IL-6R function, a viral-based gene therapy vector is assigned to the patient.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
The disclosure provides a method for treating sickle cell disease with A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13). The disclosure provides a method for increasing ADAMTS13-mediated von Willebrand factor (VWF) cleavage in a subject suffering from sickle cell disease by administering ADAMTS13. The disclosure also provides a method of treating a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease by administering ADAMTS13 after the onset of the VOC. The disclosure also provides a method of preventing a VOC in a subject suffering from sickle cell disease by administering ADAMTS13 prior to the onset of the VOC. The disclosure also provides a method of determining the efficacy of a treatment for a VOC in a mouse model.
The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor IX variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia B. In some embodiments, the present disclosure provides methods for dosing a hemophilia B patient with a polynucleotide, e.g., a codon-altered polynucleotide, encoding a Factor IX polypeptide.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
69.
METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (RVWF)
The present invention relates to a method for prophylactic treatment of spontaneous bleeding in a subject with severe von Willebrand Disease comprising administering a therapeutic amount of recombinant von Willebrand Factor (rVWF) to the subject.
The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
The invention concerns a detection method to enable the detection of complexes formed between antibodies and antigen which is endogenous to the production cell line, e.g. CHO MIF in a final product.
C07K 16/06 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux provenant de sérum
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
73.
PROTEINACEOUS MOLECULES BINDING FACTOR IXA AND FACTOR X
C07K 16/36 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de coagulation sanguine
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/36 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de coagulation sanguine
75.
BISPECIFIC ANTIBODIES BINDING FACTOR IXA AND FACTOR X
C07K 16/36 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de coagulation sanguine
C07K 16/36 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de coagulation sanguine
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A triple-plasmid system for producing recombinant adeno-associated viruses is disclosed. In one aspect, the invention is directed to a plasmid system for Recombinant Adeno-Associated Viral Vector (rAAV) production comprising: (i) a transgene-containing plasmid comprising at least one heterologous nucleic acid sequence flanked by a 5' and 3' AAV inverted terminal repeat (ITR) and a stuffer sequence outside of the ITRs; (ii) a plasmid comprising AAV replication (Rep) and capsid (Cap) gene sequences; and (iii) an adenovirus (Ad) helper plasmid.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 38/02 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
78.
POOLING DEVICE FOR SINGLE OR MULTIPLE MEDICAL CONTAINERS
A medicinal fluid pooling device may be used to pool multiple containers of medicinal fluid to facilitate administration of the medicinal fluid to a patient. A medicinal pooling device may include spikes covered by spike sheaths which are pierced when a container of medicinal fluid is inserted into the medicinal pooling device. The medicinal pooling device may also include a cover configured to cover the spikes. The medicinal pooling device may also include a fluidic interface which may be used to fluidly connect the medicinal pooling device to an infusion pump or syringe.
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61J 1/20 - Dispositions pour le transfert des liquides, p. ex. du flacon à la seringue
A61M 5/162 - Raccords à aiguilles, c.-à-d. raccordements par perforation entre le réservoir et le tube
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
A61M 39/26 - Soupapes se fermant automatiquement après déconnexion et s'ouvrant lors de la reconnexion
A container unit may be used to facilitate administrations of multiple medicinal fluids to a patient. A container unit may include a first container, a second container, and a carrier which holds the first container and the second container stationary relative to each other. The carrier may include a lip configured to engage a pooling device to secure the container unit to the pooling device. The carrier may also include a slot configured to engage an insert on the pooling device to guide the container unit as the container unit is secured to the pooling device. The carrier may also include a first portion and second portion with different shapes that are complementary to a shape of a port on the pooling device. The carrier may also include an extension which extends in a direction away from one of the first container to a level at least even with a stopper disposed in the first container. The container unit may include a lid including at least one rotation inhibitor configured to inhibit rotation of the lid about at least one axis. A plurality of container units may include container units having different volume containers while maintaining a congruent interface portions.
A61J 1/20 - Dispositions pour le transfert des liquides, p. ex. du flacon à la seringue
B65D 21/02 - Réceptacles de forme spéciale ou pourvus de garnitures ou de pièces de fixation, pour faciliter l'emboîtement, le gerbage ou l'assemblage
B65D 71/50 - Paquets d'objets maintenus ensemble par des éléments d'emballage pour la commodité du stockage ou du transport, p. ex. paquets compartimentés pour le transport à la main de plusieurs réceptacles tels que des boîtes de bière ou des bouteilles de boissons gazeusesBalles de matériaux comprenant plusieurs objets maintenus ensemble uniquement de façon partielle par des éléments d'emballage formés autrement que par liage d'un flan
An infusion pump which may include a control unit and a pump engine may be used to facilitate administration of medicinal fluids to a patient. A control unit may include a motor, a controller, a housing, and a motor coupling, where the motor coupling includes two protruding motor coupling tabs extending in a direction parallel to an output shaft of the motor. A pump engine may include a housing, a rotor disposed in the housing, and a pump coupling, where the pump coupling includes at least two protruding pump coupling tabs extending in a direction parallel to an input shaft of the rotor. The controller may be configured to change an operational mode of the infusion pump, where when the infusion pump is in a positioning mode, the controller activates the motor to move the output shaft to a predetermined angular position.
A61M 5/172 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte électriques ou électroniques
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
Embodiments disclosed herein relate to detection systems for an infusion pump. An occlusion detector for an infusion pump includes a membrane that deforms in response to fluid pressure in a fluid flow path branching off of the main fluid flow path of the infusion pump. The membrane deforms in response to fluid pressure, applying an axial pressure to a piston, which in turn triggers a force sensor. A controller of the infusion pump triggers an alarm or alerts a user when a threshold is reached. A bubble detector for the infusion pump includes a light emitter and reflective surface. Light shines through the fluid flow path, refracting differently if there is air present in the flow path. A light sensor detects the light and conveys an output signal to the controller. If detected air surpasses a threshold, the controller sounds an alarm or otherwise alerts the user.
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
A61M 5/36 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour éliminer l'air ou pour empêcher l'injection ou l'introduction d'air dans le corps
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
According to various aspects of the present application, embodiments of an infusion pump for administering medication to a patient are provided. According to one embodiment, the infusion pump automatically determines time intervals and associated rates of infusion of the medication, and automatically controls a pump engine to infuse the medication for the determined time intervals at the associated rates of infusion. According to another embodiment, the infusion pump determines whether an infusion set is configured to infuse medication into a patient at one site or at two sites. The infusion pump then controls the pump engine based on the determined configuration of the infusion set. According to another embodiment, the infusion pump automatically primes the infusion set for infusion of medication into a patient. According to another embodiment, the infusion pump automatically determines whether one or more needles have been placed on the patient correctly.
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
A61M 5/172 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte électriques ou électroniques
G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
A Factor VIII (FVIII) composition formulated such that NaCl is not present in the final formulation or is present in trace amounts, which allows for a concomitant reduction in the lyophilization cycle time and increased stability of the lyophilized FVIII.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
84.
GENE THERAPY OF HEMOPHILIA A USING VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION
The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A. In some embodiments, the present disclosure provides methods for dosing a hemophilia A patient with a polynucleotide, e.g., a codon-altered polynucleotide, encoding a Factor VIII polypeptide.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The invention is directed to a female-female syringe adapter, related systems, and methods of using the female-female adapter. The female-female syringe adapter may be used with male nozzles of syringes and reconstitution devices when reconstituting a lyophilized powder. The female-female adapter also may be used to combine doses in a common syringe from mixed reconstitution products in a multi-chambered syringe.
The AAV compositions comprising an AAV and a buffer. These AAV compositions are appropriate for us in intracerebroventricular (ICV) and intraparenchymal (IRA) administration, as well as other routes of administration and can be provided in frozen, liquid or potentially freeze dried (lyophilized) state.
A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
87.
BOTTOM SECTION FOR BEING CONNECTED TO AN ASSEMBLY WITH PLATE SETTLER, AND ASSEMBLY WITH PLATE SETTLER
This disclosure relates to a bottom section for being connected to an assembly for separating a solid component from a fluid. The assembly includes an inclined plate settler with at least one sedimentation channel for letting a solid component to be separated settle, said plate settler comprising a lower portion and an upper portion, wherein said at least one sedimentation channel extends from the lower portion to the upper portion. The bottom section is configured to be connected to the lower portion of the inclined plate settler. The bottom section comprises at least one inlet channel for feeding a fluid comprising the solid component to be separated to the plate settler, and at least one collection channel for collecting a settled solid component descending from the at least one sedimentation channel. Said at least one inlet channel and said at least one collection channel are fluidly separated from each other, said inlet channel and said collection channel being connectable to said at least one sedimentation channel, to form fluid connections between said at least one inlet channel and said at least one sedimentation channel and between said at least one collection channel and said at least one sedimentation channel, respectively.
B03B 5/30 - Lavage de matériaux en grains, en poudre ou en grumeauxSéparation par voie humide en utilisant des plongeants et flottants avec emploi de liquides denses ou de suspensions
88.
Separation of VWF and VWF propeptide by chromatographic methods
The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).
B01D 15/34 - Séparation par sélection en fonction de la taille, p. ex. chromatographie d'exclusion de tailleFiltration sur gelPerméation
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
B01D 15/38 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p. ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
C07K 1/16 - ExtractionSéparationPurification par chromatographie
The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non- covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat- VWF).
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
Provided herein are methods of producing an adeno-associated virus (AAV) product and methods of purifying adeno-associated virus. AAV is loaded onto an affinity resin, wash steps are undertaken, and AAV is eluted from the affinity resin. Various buffers are disclosed for use in the wash steps and elution.
A61K 39/23 - Parvoviridae, p. ex. virus de l'aleucémie féline
B01D 15/38 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p. ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
C07K 1/30 - ExtractionSéparationPurification par précipitation
C07K 1/36 - ExtractionSéparationPurification par une combinaison de plusieurs procédés de types différents
B01D 15/12 - Adsorption sélective, p. ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives à la préparation de l'alimentation
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
B01D 15/42 - Adsorption sélective, p. ex. chromatographie caractérisée par le mode de développement, p. ex. par déplacement ou par élution
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
92.
Methods for testing effectiveness of a von Willebrand factor used in treating von Willebrand disease (VWD)
The invention generally relates to methods of testing the effectiveness of a von Willebrand factor (VWF) in treating von Willebrand disease (VWD) in a subject comprising measuring VWF cleavage fragments in a blood sample from the subject before and after treatment. In particular, the invention relates to methods of measuring VWF cleavage fragments, wherein an increase in VWF cleavage fragments after the treatment indicates that endogenous a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in the subject is cleaving the VWF and wherein a decrease or absence of VWF cleavage fragments after the treatment indicates that endogenous ADAMTS13 in the subject is not cleaving the VWF.
C12Q 1/56 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des facteurs de coagulation du sang, p. ex. faisant intervenir la thrombine, la thromboplastine, le fibrinogène
G01N 33/86 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir le temps de coagulation du sang
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
93.
ENVIRONMENTALLY COMPATIBLE DETERGENTS FOR INACTIVATION OF LIPID-ENVELOPED VIRUSES
The present invention relates to methods for inactivating a lipid-enveloped virus using environmentally compatible detergents, and to methods for preparing a biopharmaceutical drug using environmentally compatible detergents. The invention also provides environmentally compatible detergents.
C08G 65/26 - Composés macromoléculaires obtenus par des réactions créant une liaison éther dans la chaîne principale de la macromolécule à partir d'éthers cycliques par ouverture d'un hétérocycle à partir d'éthers cycliques et d'autres composés
C08G 65/334 - Polymères modifiés par post-traitement chimique avec des composés organiques contenant du soufre
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
